Veradermics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	10.28	3.5	2.35
Research & Development	62.07	23.28	14.97
Total Operating Expenses	72.35	26.78	17.32
Operating Income	-72.35	-26.78	-17.32
Interest Income	1.56	0.48	0.87
Interest Expense	-	-0.59	-0.04
Other Non-Operating Income (Expense)	0.79	0.39	-
Total Non-Operating Income (Expense)	2.35	0.29	0.83
Pretax Income	-70	-26.49	-16.49
Net Income	-70	-26.49	-16.49
Net Income to Common	-83.37	-27.3	-16.49
Shares Outstanding (Basic)	1	1	1
Shares Outstanding (Diluted)	1	1	1
Shares Change (YoY)	1.09%	-	-
EPS (Basic)	-111.91	-37.05	-22.38
EPS (Diluted)	-111.91	-37.05	-22.38
Free Cash Flow	-71.63	-23.69	-13.51
Free Cash Flow Per Share	-96.14	-32.14	-18.33
EBITDA	-72.35	-26.78	-17.32
EBIT	-72.35	-26.78	-17.32

SEC Filings: 10-K · 10-Q